



# Pooled Analysis of Phase 1 Single-Agent Trials in NSCLC: Response Rates and Toxicity Over the Last Decade

A. Kouli, MD , A. Hamad, MD, K. Benkhadra, MD, B. Hasan, MD, Z. Bin Riaz, MD , M. Biondi, MD, A. Alsulaiman, MD, H.C. Kalangi, V. Ernani, MD, A. Hazim, MD

1 Mayo clinic, Phoenix, AZ, USA 2 Mayo Clinic, Rochester, MN, US A3 Valleywise Health, Phoenix, AZ, USA


## BACKGROUND

**Context:** NSCLC accounts for 85% of lung cancer; phase 1 trials offer critical options post-standard therapy.  
**Objective:** Characterize Overall Response Rate (ORR) and toxicity profiles of single-agent phase 1 trials in advanced NSCLC (2016–2026).

## METHODS

**Design:** Systematic review and pooled analysis (PRISMA guidelines).  
**Search:** PubMed, EMBASE, Cochrane, ASCO/ESMO (2016–2026).  
**Inclusion:** Phase 1 monotherapy trials in advanced NSCLC reporting efficacy/safety


## PRISMA FLOW DIAGRAM



| Drug Class                        | Grade 3+ TRAE |
|-----------------------------------|---------------|
| ALK/ROS1/RET/NTRK TKIs            | 40%           |
| Third-gen EGFR TKIs               | 28%           |
| EGFR exon 20 insertion inhibitors | 32%           |
| Antibody-Drug Conjugates (ADCs)   | 34.8%         |
| PD-1/PD-L1 inhibitors             | 14.3%         |

## RESULTS

### POOLED OBJECTIVE RESPONSE RATE (ORR) BY DRUG CLASS



## CONCLUSION

Modern phase 1 trials yield meaningful clinical benefit, especially with molecular profiling and targeted agents. High heterogeneity and single-arm limitations necessitate cautious interpretation and confirmatory trials.

## REFERENCES

- Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371-2381. doi:10.1056/NEJMoa2103695
- Sacher A, LoRusso P, Patel MR, et al. Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation. N Engl J Med. 2023;389(8):710-721. doi:10.1056/NEJMoa2303810
- Leighl NB, Hellmann MD, Hui R, et al. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. Lancet Respir Med. 2019;7(4):347-357. doi:10.1016/S2213-2600(18)30500-9
- Horn L, Gettinger SN, Gordon MS, et al. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. Eur J Cancer. Download PDF 2018;101:201-209. doi:10.1016/j.ejca.2018.06.031
- Gulley JL, Rajan A, Spigel DR, et al. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncol. Download PDF 2017;18(5):599-610. doi:10.1016/S1470-2045(17)30240-1